Analysis of the LRRK2 p.G2019S mutation in Colombian Parkinson’s Disease Patients
Abstract
Introduction: Mutations in the leucine-rich repeat kinase 2 gene (LRRK2 or Dardarin) are considered to be a common cause of autosomal dominant and sporadic Parkinson´s disease, but the prevalence of these mutations varies among populations. Objective: to analysed the frequency of the LRRK2 p.G2019S mutation (c.6055G>A transition) in a sample of Colombian patients. Materials and Methods: In the present study we have analysed the frequency of the LRRK2 p.G2019S mutation in 154 patients with familial or sporadic Parkinson Disease, including early and late onset patients, and 162 normal controls. Results: Our results show occurrence of this mutation in two cases (2/154, 1.3%) with classical Parkinson´s signs, and one completely asymptomatic control (1/162, 0.6%). Conclusion: The p.G2019S mutation is not an important causal factor of Parkinson Disease in Colombia having similar frequencies to those reported in other Latin American populations.
Authors
Downloads
Keywords
- Parkinson´s disease
- LRRK2
- G2019S
- Colombia
References
(1) Khandhar SM, Marks WJ. Epidemiology of Parkinson's disease. Dis Mon 2007; 53(4): 200-5.
(2) Zhang ZX, Roman GC. Worldwide occurrence of Parkinson's disease: an updated review. Neuroepidemiology 1993; 12(4): 195-208.
(3) de Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez-Pousa S, et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J NeurolNeurosurgPsychiatry 1997; 62(1):10-5.
(4) Pradilla G., Vesga B.E., León-Sarmiento F.E., grupo GENECO. Estudio neuroepidemiológico nacional (EPINEURO) colombiano. Pan Am J PublicHealth 2003; 14 (2):104-11.
(5) Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008; 79(4): 368-76.
(6) Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55(3): 181-4.
(7) Vermersch P, Delacourte A, Javoy-Agid F, Hauw JJ, Agid Y. Dementia in Parkinson's disease: biochemical evidence for cortical involvement using the immunodetection of abnormal Tau proteins. Ann Neurol 1993; 33(5): 445-50.
(8) Jellinger KA. Recent developments in the pathology of Parkinson's disease. J Neural Transm Suppl 2002; (62): 347-76.
(9) Elbaz A, Grigoletto F, Baldereschi M, Breteler MM, Manubens-Bertran JM, Lopez-Pousa S, et al. Familial aggregation of Parkinson's disease: a population-based case-control study in Europe. EUROPARKINSON Study Group. Neurology 1999; 52(9): 1876-82.
(10) Dawson TM, Dawson VL. Molecular pathways of neurodegeneration in Parkinson's disease. Science 2003; 302(5646): 819-22.
(11) Zhang Y, Dawson VL, Dawson TM. Oxidative stress and genetics in the pathogenesis of Parkinson's disease. Neurobiol Dis 2000; 7(4): 240-50.
(12) Riess O, Kruger R. Parkinson's disease--a multifactorial neurodegenerative disorder. J Neural Transm Suppl 1999; 56:113-25.
(13) Douglas MR, Lewthwaite AJ, Nicholl DJ. Genetics of Parkinson's disease and parkinsonism. Expert Rev Neurother 2007; 7(6): 657-66.
(14) Piccini P, Burn DJ, Ceravolo R, Maraganore D, Brooks DJ. The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol 1999; 45(5): 577-82.
(15) Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, Bressman S, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008; 7(7): 583-90.
(16) Nichols WC, Pankratz N, Hernandez D, Paisan-Ruiz C, Jain S, Halter CA, et al. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet 2005; 365(9457): 410-2.
(17) Ishihara L, Gibson RA, Warren L, Amouri R, Lyons K, Wielinski C, et al. Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families. Mov Disord 2007; 22(1): 55-61.
(18) Lesage S, Ibanez P, Lohmann E, Pollak P, Tison F, Tazir M, et al. G2019S LRRK2 mutation in French and North African families with Parkinson's disease. Ann Neurol 2005; 58(5): 784-7.
(19) Pimentel MM, Moura KC, Abdalla CB, Pereira JS, de Rosso AL, Nicaretta DH, et al. A study of LRRK2 mutations and Parkinson's disease in Brazil. NeurosciLett 2008; 433(1): 17-21.
(20) Perez-Pastene C, Cobb SA, az-Grez F, Hulihan MM, Miranda M, Venegas P, et al. Lrrk2 mutations in South America: A study of Chilean Parkinson's disease. Neurosci Lett 2007; 422(3): 193-7.
(21) Daniel SE, Lees AJ. Parkinson's Disease Society Brain Bank, London: overview and research. J Neural Transm Suppl 1993; 39:165-72.
(22) Ozelius LJ, Senthil G, Saunders-Pullman R, Ohmann E, Deligtisch A, Tagliati M, et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med 2006; 354(4):424-5.
(23) Kachergus J, Mata IF, Hulihan M, Taylor JP, Lincoln S, Aasly J, et al. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet 2005; 76(4): 672-80.
(24) Kay DM, Zabetian CP, Factor SA, Nutt JG, Samii A, Griffith A, et al. Parkinson's disease and LRRK2: frequency of a common mutation in U.S. movement disorder clinics. Mov Disord 2006; 21(4): 519-23.
(25) De Rosa A, De Michele G, Guacci A, Carbone R, Lieto M, Peluso S, et al.. Genetic screening for the LRRK2 R1441C and G2019S mutations in Parkinsonian patients from campania. J Parkinsons Dis. 2014; 4(1):123-8.
(26) Munhoz RP, Wakutani Y, Marras C, Teive HA, Raskin S, Werneck LC, et al. The G2019S LRRK2 mutation in Brazilian patients with Parkinson's disease: phenotype in monozygotic twins. Mov Disord 2008; 23(2): 290-4.
(27) Tan EK, Shen H, Tan LC, Farrer M, Yew K, Chua E, et al. The G2019S LRRK2 mutation is uncommon in an Asian cohort of Parkinson's disease patients. Neurosci Lett 2005; 384(3): 327-9.
(28) Zabetian CP, Hutter CM, Yearout D, Lopez AN, Factor SA, Griffith A, et al. LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago. Am J Hum Genet 2006; 79(4): 752-8.
(29) Mata IF, Cosentino C, Marca V, Torres L, Mazzetti P, Ortega O, et al. LRRK2 mutations in patients with Parkinson’s disease from Peru and Uruguay. Parkinsonism and Related Disorders 15 2009; 15: 370–373.
(30) Gatto EM, Parisi V, Converso DP, Poderoso JJ, Carreras MC, Martí-Massó JF, Paisán-Ruiz C. The LRRK2 G2019S mutation in a series of Argentinean patients with Parkinson's disease: clinical and demographic characteristics. Neurosci Lett. 2013; 537: 1-5.
(31) Gaig C, Ezquerra M, Marti MJ, Munoz E, Valldeoriola F, Tolosa E. LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance. Arch Neurol 2006; 63(3): 377-82.
(32) Infante J, Rodriguez E, Combarros O, Mateo I, Fontalba A, Pascual J, et al. LRRK2 G2019S is a common mutation in Spanish patients with late-onset Parkinson's disease. Neurosci Lett 2006; 395(3): 224-6.
(33) Mata IF, Ross OA, Kachergus J, Huerta C, Ribacoba R, Moris G, et al. LRRK2 mutations are a common cause of Parkinson's disease in Spain. Eur J Neurol 2006; 13(4): 391-4.
Copyright (c) 2015 Universidad del Valle
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The copy rights of the articles published in Colombia Médica belong to the Universidad del Valle. The contents of the articles that appear in the Journal are exclusively the responsibility of the authors and do not necessarily reflect the opinions of the Editorial Committee of the Journal. It is allowed to reproduce the material published in Colombia Médica without prior authorization for non-commercial use
